Preoperative Systemic Immune-Inflammation Index (SII) for Predicting the Survival of Patients with Stage I-III Gastric Cancer with a Signet-Ring Cell (SRC) Component
Table 1
Characteristics of 512 patients with gastric cancer with an SRC component.
Variables
Value (%)
Sex
Men
332 (64.8)
Women
180 (35.2)
Age (years)
<55
246 (48.0)
≥55
266 (52.0)
SRCC
pSRCC
68 (13.3)
mSRCC
444 (86.7)
Chemotherapy
Yes
244 (47.7)
No
268 (52.3)
Tumor size(cm)
<4.75
228 (44.5)
≥4.75
284 (55.5)
pT
T1
84 (16.4)
T2
64 (12.5)
T3
62 (12.1)
T4
302 (59.0)
pN
N0
166 (32.4)
N1
86 (16.8)
N2
100 (19.5)
N3a
102 (19.9)
N3b
58 (11.4)
pTNM
I+II
220 (43.0)
III
292 (57.0)
Tumor location
Lower stomach
328 (64.1)
Middle stomach
75 (14.6)
Upper stomach
35 (6.8)
LM stomach
53 (10.3)
MU stomach
7 (1.4)
LMU stomach
14 (2.8)
Leukocyte
<6.17
292 (57.0)
≥6.17
220 (43.0)
Neutrophil
<3.27
260 (50.8)
≥3.27
252 (49.2)
Hemoglobin
<121.2
140 (27.3)
≥121.2
372 (72.7)
Fibrinogen
<3.06
268 (52.3)
≥3.06
244 (47.7)
Prealbumin
<234.5
247 (48.2)
≥234.5
265 (51.8)
Albumin
<42.5
292 (57.0)
≥42.5
220 (43.0)
Globulin
<29.9
425 (83.0)
≥29.9
87 (17.0)
SII
<527
340 (66.4)
≥527
172 (33.6)
PNI
<48.73
176 (34.4)
≥48.73
336 (65.6)
Total gastrectomy
Yes
113 (22.1)
No
399 (77.9)
NLR
<2.2
340 (66.4)
≥2.2
172 (33.6)
SRC: signet-ring cell; SRCC: signet-ring cell carcinoma; pSRCC: pure signet-ring cell cancer; mSRCC: mixed signet-ring cell cancer; LM: lower and middle; MU: middle and upper; LMU: lower, middle, and upper; SII: systemic immune-inflammation index; PNI: prognostic nutritional index; NLR: lymphocyte to neutrophil ratio.